Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04376333 · ClinicalTrials.gov registry record · NA
Individualized Assessment and Treatment for TMD
A NA study, sponsored by UConn Health.
- Active
- Registry status
- NA
- Development phase
- 160
- Enrollment target
NCT04376333: Active NA study, sponsored by UConn Health.
NCT04376333 is a NA study that is active but no longer recruiting, run by UConn Health. The registered enrollment target is 160 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04376333, a NA study, is active but no longer recruiting, sponsored by UConn Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 160 participants
- Enrollment target
Study Summary
Temporomandibular/orofacial pain disorders (TMD) are a group of painful conditions with multiple determinants.This proposal has two main goals: 1) to test a highly individualized, adaptive treatment for TMD that has potential to be more effective than other psychosocial treatments; and 2) to discover the mechanisms by which psychosocial treatments work in chronic pain. TMD patients (N=160) will be randomized to receive standard care (STD) + an individualized assessment and treatment program (IATP) or to standard care + conventional cognitive-behavioral treatment (STD+CBT). It is expected that the STD+IATP treatment will yield lower pain, depression and interference scores over time than STD+CBT, and that changes in coping ability will mediate the treatment effects on outcomes.
Primary Outcome
Characteristic Pain Intensity will be calculated by averaging the ratings of current pain, average pain, and worst pain in the past week from the Graded Chronic Pain Scale (GCPS; Von Korff et al., 1992). Each item is scored from 0 -10.
Interventions
- BEHAVIORAL Cognitive-Behavioral Treatment
- BEHAVIORAL Individualized Assessment and Treatment Program
- OTHER Standard Conservative Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2021-02-03 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What the registry record for NCT04376333 still lists
NCT04376333 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 3 interventions - of which Cognitive-Behavioral Treatment is the first listed.
NCT04376333 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04376333 about?
NCT04376333 is a clinical study titled "Individualized Assessment and Treatment for TMD". Temporomandibular/orofacial pain disorders (TMD) are a group of painful conditions with multiple determinants.This proposal has two main goals: 1) to test a highly individualized, adaptive treatment for TMD that has potential to be more effective than other psychosocial treatments; and 2) to discove...
What is the current status of trial NCT04376333?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2021-02-03. Estimated completion is 2027-06-30.
What interventions are being tested in trial NCT04376333?
The interventions under investigation include: Cognitive-Behavioral Treatment (BEHAVIORAL), Individualized Assessment and Treatment Program (BEHAVIORAL), Standard Conservative Care (OTHER).
Who is sponsoring clinical trial NCT04376333?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04376333's enrollment target sits among peer trials
160 628th of 2000 higher than 1,347 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI